Biotech | August 11, 2021
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
If approved it will bring a second source of MMR vaccine to the US market
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Filing for WHO Emergency Use Authorisation this month
The government has recently enhanced the incentive granted to storeowners from existing Rs. 2.50 lakh to Rs. 5.00 lakh given at the rate of 15% of monthly purchases made, subject to a ceiling of Rs. 15,000 per month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Subscribe To Our Newsletter & Stay Updated
